# Mettler Toledo International Inc/: Form 10-Q for the period ended Mar 31, 2021

- Company: [Mettler Toledo International Inc/](/companies/mtd.md) (CIK 1037646)
- Form: 10-Q
- Filed: 2021-05-07
- Accepted by EDGAR: May 7, 2021, 11:20 ET
- Period: 2021-03-31
- Accession: 0001037646-21-000019
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1037646/000103764621000019/mtd-20210331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1037646/000103764621000019/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-01-01 to 2021-03-31 | $804.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Gross profit | 3 months, 2021-01-01 to 2021-03-31 | $471.7m | us-gaap:GrossProfit |
| Research and development | 3 months, 2021-01-01 to 2021-03-31 | $39.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2021-01-01 to 2021-03-31 | $221.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months, 2021-01-01 to 2021-03-31 | $9.5m | us-gaap:InterestExpense |
| Income tax | 3 months, 2021-01-01 to 2021-03-31 | $35.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-01-01 to 2021-03-31 | $149.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-01-01 to 2021-03-31 | $6.32 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-01-01 to 2021-03-31 | $6.41 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-01-01 to 2021-03-31 | 23,685,665 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2021-01-01 to 2021-03-31 | $158.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2021-01-01 to 2021-03-31 | $24.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months, 2021-01-01 to 2021-03-31 | $262.5m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2021-03-31 | $106.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-03-31 | $1.08bn | us-gaap:AssetsCurrent |
| Total assets | at 2021-03-31 | $3.03bn | us-gaap:Assets |
| Current liabilities | at 2021-03-31 | $841.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-03-31 | $2.83bn | us-gaap:Liabilities |
| Long-term debt | at 2021-03-31 | $1.56bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2021-03-31 | $202.6m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2021-03-31 | 23,269,421 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 28,427 characters.

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the Unaudited Interim Consolidated Financial Statements included herein.*

### General

Our interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the full year ending December 31, 2021.

Changes in local currencies exclude the effect of currency exchange rate fluctuations. Local currency amounts are determined by translating current and previous year consolidated financial information at an index utilizing historical currency exchange rates. We believe local currency information provides a helpful assessment of business performance and a useful measure of results between periods. We do not, nor do we suggest that investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. We present non-GAAP financial measures in reporting our financial results to provide investors with an additional analytical tool to evaluate our operating results.

We also include in the discussion below disclosures of immaterial qualitative factors that are not quantified. Although the impact of such factors is not considered material, we believe these disclosures can be useful in evaluating our operating results.

### COVID-19

The ongoing coronavirus pandemic ("COVID-19") pandemic has resulted in millions of confirmed cases throughout the world and in all countries where we conduct business. The outbreak has caused many governments to implement stay-at-home orders, quarantines, and significant restrictions on travel. Several governments have also implemented work restrictions that prohibit many employees from going to their customary work locations and that require these employees to work remotely if possible. These restrictions continue to change as COVID-19 evolves in each country and region.

The health and safety of our employees and business partners have been our highest priority throughout the COVID-19 pandemic, and we have implemented several preventative and protective measures. We have also continued to support our customers with their essential businesses such as life sciences, food manufacturing, chemicals (e.g., sanitizers, disinfectants, soaps, etc.), food retail, and transportation and logistics. Our production and logistics facilities are currently operational, and our office-based employees have been able to work remotely in adherence to applicable jurisdictional stay-at-home orders. Our supply chain is currently continuing with minimal interruption, and we generally maintain adequate product inventory levels and safety stock for certain components. We continue to leverage our digital and remote sales and service capabilities, while also meeting delivery requirements with our global supply chain. Our service organization also continues to provide on-site and remote customer support to facilitate uptime, productivity, and regulatory compliance.

COVID-19 presents several risks to our business as further described in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020. Uncertainties related to COVID-19 and the resulting impact to the global economy continue in most regions of the world and market conditions can change quickly. The longer-term effects on our business will be impacted by the global economy and any recession implications in different regions of the world.

### Results of Operations – Consolidated

The following tables set forth items from our interim consolidated statements of operations and comprehensive income for the three month periods ended March 31, 2021 and 2020 (amounts in thousands).

|  | Three months ended March 31, 2021 (unaudited)% |  | 2020 (unaudited)% |  |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $804,390 | 100.0 | $649,162 | 100.0 |
| Cost of sales | 332,694 | 41.4 | 274,753 | 42.3 |
| Gross profit | 471,696 | 58.6 | 374,409 | 57.7 |
| Research and development | 39,272 | 4.9 | 34,387 | 5.3 |
| Selling, general and administrative | 221,752 | 27.6 | 198,744 | 30.6 |
| Amortization | 13,884 | 1.7 | 13,998 | 2.2 |
| Interest expense | 9,471 | 1.2 | 10,219 | 1.6 |
| Restructuring charges | 1,193 | 0.1 | 1,905 | 0.3 |
| Other charges (income), net | 710 | 0.1 | (3,343) | (0.5) |
| Earnings before taxes | 185,414 | 23.0 | 118,499 | 18.2 |
| Provision for taxes | 35,751 | 4.4 | 20,384 | 3.1 |
| Net earnings | $149,663 | 18.6 | $98,115 | 15.1 |

#### Net sales

Net sales were $804.4 million for the three months ended March 31, 2021, compared to $649.2 million for the corresponding period in 2020. This represents an increase in U.S. dollars of 24%. Excluding the effect of currency exchange rate fluctuations, or in local currencies, net sales increased 18% for the three months ended March 31, 2021. We experienced broad-based growth with improved customer demand in most businesses and regions and strong execution of our sales and marketing programs. Growth in China was particularly strong, which also benefited from a prior year sales decline relating to COVID-19. However, uncertainty relating to COVID-19 continues and market conditions may change quickly.

Net sales by geographic destination for the three months ended March 31, 2021 in U.S. dollars increased 15% in the Americas, 24% Europe and 37% in Asia/Rest of World. In local currencies, our net sales by geographic destination increased 14% in both the Americas and Europe. Asia/Rest of World increased 29% in local currencies for the three months ended March 31, 2021 compared to the corresponding period in 2020, with 44% growth in China compared to a 13% local currency China sales decline during the three months ended March 31, 2020 versus the corresponding period in 2019. A discussion of sales by operating segment is included below.

As described in Note 19 to our consolidated financial statements for the year ended December 31, 2020, our net sales comprise product sales of precision instruments and related services. Service revenues are primarily derived from repair and other services, including regulatory compliance qualification, calibration, certification, preventative maintenance and spare parts.

Net sales of products increased 28% in U.S. dollars and 23% in local currency for the three months ended March 31, 2021 compared to the prior period. Service revenue (including spare parts) increased 11% in U.S. dollars and 6% in local currency during the three months ended March 31, 2021 compared to the corresponding period in 2020.

Net sales of our laboratory products and services, which represented approximately 55% of our total net sales for the three months ended March 31, 2021, increased 25% in U.S. dollars and 20% in local currencies during the three months ended March 31, 2021. The local currency increase in net sales of our laboratory-related products includes very strong growth in most product categories, especially pipettes. Our laboratory-related products experienced strong growth in biopharma, improved customer demand in various other end markets, and also continued to benefit from COVID-19 testing and vaccine development and production activities.

Net sales of our industrial products and services, which represented approximately 39% of our total net sales for the three months ended March 31, 2021, increased 23% in U.S. dollars and 17% in local currencies during the three months ended March 31, 2021. The local currency increase in net sales of our industrial-related products for the three months ended March 31, 2021 includes particularly strong growth in core industrial products in each region, especially China.

Net sales in our food retailing products and services, which represented approximately 6% of our total net sales for the three months ended March 31, 2021, increased 23% in U.S. dollars and 13% in local currencies during the three months ended March 31, 2021. The increase in food retailing is primarily due to improved project activity in Europe and Asia/Rest of World.

#### Gross profit

Gross profit as a percentage of net sales was 58.6% for the three months ended March 31, 2021 compared to 57.7% for the corresponding period in 2020.

Gross profit as a percentage of net sales for products was 60.9% and 60.8% for the three month periods ended March 31, 2021 and 2020.

Gross profit as a percentage of net sales for services (including spare parts) was 50.7% for the three months ended March 31, 2021 compared to 48.0% for the corresponding period in 2020.

The increase in gross profit as a percentage of net sales for the three months ended March 31, 2021 primarily reflects increased sales volume and favorable price realization, partially offset by higher transportation and material costs.

#### Research and development and selling, general and administrative expenses

Research and development expenses as a percentage of net sales was 4.9% for the three months ended March 31, 2021 compared to 5.3% in the corresponding period during 2020, respectively. Research and development expenses increased 14% in U.S. dollars and 7% in local currencies, during the three months ended March 31, 2021 compared to the corresponding period in 2020. The local currency increase includes the timing of project activity.

Selling, general and administrative expenses as a percentage of net sales were 27.6% for the three months ended March 31, 2021 compared to 30.6% in the corresponding period during 2020, respectively Selling, general and administrative expenses increased 12% in U.S. dollars and 7% in local currencies, during the three months ended March 31, 2021 compared to the corresponding period in 2020. The local currency increase includes higher cash incentive expense, offset in part by benefits from our temporary and ongoing cost savings initiatives.

#### Amortization, interest expense, other charges (income), net and taxes

Amortization expense was $13.9 million for the three months ended March 31, 2021 and $14.0 million for the corresponding period in 2020.

Interest expense was $9.5 million for the three months ended March 31, 2021 and $10.2 million for the corresponding period in 2020.

Other charges (income), net includes non-service pension costs (benefits), net (gains) losses from foreign currency transactions and hedging activities, interest income and other items. Non-service pension benefits for the three months ended March 31, 2021 and 2020 were $2.5 million and $3.0 million, respectively. Other charges (income), net also included $2.8 million of acquisition costs for the three months ended March 31, 2021.

Our reported tax rate was 19.3% and 17.2% during the three months ended March 31, 2021 and 2020, respectively. The provision for taxes is based upon using our projected annual effective tax rate of 19.5% and 21.5% before non-recurring discrete tax items for the three months ended March 31, 2021 and 2020, respectively. The difference between our projected annual effective tax rate and the reported tax rate is related to the timing of excess tax benefits associated with stock option exercises.

### Results of Operations – by Operating Segment

The following is a discussion of the financial results of our operating segments. We currently have five reportable segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations and Other. A more detailed description of these segments is outlined in Note 19 to our consolidated financial statements for the year ended December 31, 2020.

#### U.S. Operations (amounts in thousands)

|  | Three months ended March 31, |  |
| --- | ---: | ---: |
|  | 2021 | 2020% |
| Total net sales | $308,743 | $267,800 15% |
| Net sales to external customers | $271,959 | $241,409 13% |
| Segment profit | $63,671 | $44,938 42% |

Total net sales and net sales to external customers increased 15% and 13%, respectively for the three months ended March 31, 2021 compared with the corresponding period in 2020. The increase in total net sales and net sales to external customers for the three months ended March 31, 2021 includes very strong growth in laboratory products, especially pipettes, and core industrial, partially offset by declines in food retailing and product inspection.

Segment profit increased $18.7 million for the three months ended March 31, 2021 compared to the corresponding period in 2020. Segment profit during the three months ended March 31, 2021 includes higher net sales volume and benefits from our margin expansion and cost savings initiatives.

#### Swiss Operations (amounts in thousands)

|  | Three months ended March 31, 2021 | 2020 | %1) |
| --- | ---: | ---: | ---: |
| Total net sales | $223,746 | $184,745 | 21% |
| Net sales to external customers | $39,281 | $31,897 | 23% |
| Segment profit | $64,879 | $53,910 | 20% |

1\) Represents U.S. dollar growth.

Total net sales increased 21% in U.S. dollars and 14% in local currency for the three months ended March 31, 2021 compared to the corresponding period in 2020. Net sales to external customers increased 23% in U.S. dollars and 17% in local currency during the three months ended March 31, 2021 compared to the corresponding period in 2020. The increase in local currency net sales to external customers for the three month period ended March 31, 2021 includes strong growth in most product categories, especially process analytics.

Segment profit increased $11.0 million for the three month period ended March 31, 2021 compared to the corresponding period in 2020. Segment profit during the three months ended March 31, 2021 includes higher net sales volume, benefits of our cost savings initiatives and favorable foreign currency translation.

#### Western European Operations (amounts in thousands)

|  | Three months ended March 31, 2021 | 2020 | %1) |
| --- | ---: | ---: | ---: |
| Total net sales | $244,605 | $195,040 | 25% |
| Net sales to external customers | $192,350 | $153,325 | 25% |
| Segment profit | $37,866 | $24,107 | 57% |

1\) Represents U.S. dollar growth.

Total net sales increased 25% in U.S. dollars and 15% in local currencies during the three months period ended March 31, 2021 compared to the corresponding period in 2020. Net sales to external customers increased 25% in U.S. dollars and 14% in local currencies during the three months period ended March 31, 2021 compared to the corresponding period in 2020. Local currency net sales to external customers for the three months ended March 31, 2021 includes very strong growth in most product categories with particularly strong growth in pipettes.

Segment profit increased $13.8 million for the three month period ended March 31, 2021 compared to the corresponding period in 2020. Segment profit increased during the three months ended March 31, 2021 primarily due to higher net sales volume, benefits of our cost savings initiatives and favorable foreign currency translation.

#### Chinese Operations (amounts in thousands)

|  | Three months ended March 31, 2021 | 2020 | %1) |
| --- | ---: | ---: | ---: |
| Total net sales | $225,152 | $149,348 | 51% |
| Net sales to external customers | $156,074 | $100,599 | 55% |
| Segment profit | $72,024 | $45,550 | 58% |

1\) Represents U.S. dollar growth.

Total net sales increased 51% in U.S. dollars and 40% in local currency for the three months ended March 31, 2021 compared to the corresponding period in 2020. Net sales to external customers by origin increased 55% in U.S. dollars and 44% in local currency during the three months ended March 31, 2021 compared to the corresponding period in 2020. The increase in local currency net sales to external customers during the three months ended March 31, 2021 reflects particularly strong growth in most product categories, especially industrial-related products. We have experienced significant improvement in customer demand in most product categories, and also benefited from the previous year local currency sales decline of 15% during the three months ended March 31, 2020 versus the corresponding period in 2019 due to the impact of COVID-19 and related governmental restrictions. However, market conditions may change quickly and we will start to face more difficult prior period comparisons during the remainder of 2021.

Segment profit increased $26.5 million for the three month period ended March 31, 2021 compared to the corresponding period in 2020. The increase in segment profit for the three month period ended March 31, 2021 primarily includes increased sales volume, benefits from our cost savings measures and favorable foreign currency translation.

#### Other (amounts in thousands)

|  | Three months ended March 31, 2021 | 2020 | %1) |
| --- | ---: | ---: | ---: |
| Total net sales | $145,821 | $122,828 | 19% |
| Net sales to external customers | $144,726 | $121,932 | 19% |
| Segment profit | $20,172 | $11,026 | 83% |

1\) Represents U.S. dollar growth.

Total net sales and net sales to external customers both increased 19% in U.S. dollars and 14% in local currencies during the three month period ended March 31, 2021 compared to the corresponding period in 2020. The increase in net sales to external customers includes strong growth in most product categories.

Segment profit increased $9.1 million for the three months ended March 31, 2021 compared to the corresponding period in 2020. The increase in segment profit is primarily related to increased sales volume and favorable foreign currency translation.

### Liquidity and Capital Resources

Liquidity is our ability to generate sufficient cash flows from operating activities to meet our obligations and commitments. In addition, liquidity includes available borrowings under our Credit Agreement, the ability to obtain appropriate financing and our cash and cash equivalent balances. Currently, our liquidity needs are primarily driven by working capital requirements, capital expenditures, share repurchases and acquisitions.

Cash provided by operating activities totaled $158.9 million during the three months ended March 31, 2021, compared to $65.5 million in the corresponding period in 2020. The increase in 2021 is primarily due to higher net earnings as well as favorable working capital and the timing of tax payments.

Capital expenditures are made primarily for investments in information systems and technology, machinery, equipment and the purchase and expansion of facilities. Our capital expenditures totaled $24.6 million for the three months ended March 31, 2021 compared to $18.8 million in the corresponding period in 2020. We expect to make net investments in new or expanded manufacturing facilities of $10 million to $15 million in 2021.

#### Senior Notes and Credit Facility Agreement

Our debt consisted of the following at March 31, 2021:

|  | March 31, 2021 U.S. Dollar | Other Principal Trading Currencies | Total |
| --- | ---: | ---: | ---: |
| 3.67% $50 million ten-year Senior Notes due December 17, 2022 | $50,000 | $— | $50,000 |
| 4.10% $50 million ten-year Senior Notes due September 19, 2023 | 50,000 | — | 50,000 |
| 3.84% $125 million ten-year Senior Notes due September 19, 2024 | 125,000 | — | 125,000 |
| 4.24% $125 million ten-year Senior Notes due June 25, 2025 | 125,000 | — | 125,000 |
| 3.91% $75 million ten-year Senior Notes due June 25, 2029 | 75,000 | — | 75,000 |
| 3.19% $50 million fifteen-year Senior Notes due January 24, 2035 | 50,000 | — | 50,000 |
| 1.47% Euro 125 million fifteen-year Senior Notes due June 17, 2030 | — | 147,197 | 147,197 |
| 1.30% Euro 135 million fifteen-year Senior Notes due November 6, 2034 | — | 158,973 | 158,973 |
| 1.06% Euro 125 million fifteen-year Senior Notes due March 19, 2036 | — | 147,197 | 147,197 |
| Senior notes debt issuance costs, net | (1,073) | (1,610) | (2,683) |
| Total Senior Notes | 473,927 | 451,757 | 925,684 |
| $1.1 billion Credit Agreement, interest at LIBOR plus 87.5 basis points | 505,605 | 127,637 | 633,242 |
| Other local arrangements | 2,196 | 52,437 | 54,633 |
| Total debt | 981,728 | 631,831 | 1,613,559 |
| Less: current portion | (222) | (52,283) | (52,505) |
| Total long-term debt | $981,506 | $579,548 | $1,561,054 |

As of March 31, 2021, approximately $460.7 million of additional borrowings was available under our Credit Agreement, and we maintained $106.7 million of cash and cash equivalents. During the three months ended March 31, 2021, the Company increased its long-term debt primarily due to the funding of the PendoTECH acquisition as described in Note 4. Changes in exchange rates between the currencies in which we generate cash flows and the currencies in which our borrowings are denominated affect our liquidity. In addition, because we borrow in a variety of currencies, our debt balances fluctuate due to changes in exchange rates. Further, we do not have any downgrade triggers relating to ratings from rating agencies that would accelerate the maturity dates of our debt.

We currently believe that cash flow from operating activities, together with liquidity available under our Credit Agreement and local working capital facilities and our cash balances, will be sufficient to fund currently anticipated working capital needs and capital spending requirements for the foreseeable future.

In December 2020, the Company entered into an agreement to issue and sell EUR 125.0 million of 15-year 1.06% Euro Senior Notes ("1.06% Euro Senior Notes"). The terms of the Euro Senior Notes are consistent with the previous Euro Senior Notes as described in the Company's Annual Report on Form 10-K for the year ended December 31, 2020. The Company also entered into a forward contract to receive $152.1 million at the time of issuing the 1.06% Euro Senior Notes in March 2021. The Company issued the 1.06% Euro Senior Notes with a fixed interest rate of 1.06% in March 2021. The 1.06% Euro Senior Notes are unsecured obligations of the Company and will mature on March 19, 2036. Interest on the 1.06% Euro Senior Notes is payable semi-annually in March and September of each year.

In 2018, two of the Company's non-U.S. pension plans issued loans totaling $39.6 million (Swiss franc 38 million) to a wholly owned subsidiary of the Company. The loans have the same terms and conditions which include an interest rate of Swiss franc LIBOR plus 87.5 basis points. The loans were renewed for one year in April 2021.

We continue to explore potential acquisitions. In connection with any acquisition, we may incur additional indebtedness. In March 2021, we acquired all the membership interests of Mayfair Technology, LLC, ("PendoTECH") a manufacturer and distributor of single-use sensors, transmitters, control systems and software for measuring, monitoring and data collection primarily in bioprocess applications. PendoTECH serves bio-pharmaceutical manufacturers and life science laboratories and is located in the United States. The initial cash payment was $185.0 million and we may be required to pay additional consideration of up to $20.0 million and other post-closing amounts. For additional information related to the PendoTECH acquisition refer to Note 4 to the interim consolidated financial statements.

#### Share Repurchase Program

In November 2020, the Company's Board of Directors authorized an additional $2.5 billion to the share repurchase program which has $2.8 billion of remaining availability as of March 31, 2021. The share repurchases are expected to be funded from cash generated from operating activities, borrowings, and cash balances. Repurchases will be made through open market transactions, and the amount and timing of purchases will depend on business and market conditions, the stock price, trading restrictions, the level of acquisition activity, and other factors.

We have purchased 29.7 million common shares since the inception of the program in 2004 through March 31, 2021. During the three months ended March 31, 2021 and 2020, we spent $262.5 million and $200.0 million on the repurchase of 224,808 shares and 268,161 shares at an average price per share of $1,167.64 and $745.80, respectively. We reissued 22,388 shares and 50,372 shares held in treasury for the exercise of stock options and restricted stock units during the three months ended March 31, 2021 and 2020, respectively.

### Effect of Currency on Results of Operations

Our earnings are affected by changing exchange rates. We are most sensitive to changes in the exchange rates between the Swiss franc, euro, Chinese renminbi, and U.S. dollar. We have more Swiss franc expenses than we do Swiss franc sales because we develop and manufacture products in Switzerland that we sell globally, and have a number of corporate functions located in Switzerland. When the Swiss franc strengthens against our other trading currencies, particularly the U.S. dollar and euro, our earnings decrease. We also have significantly more sales in the euro than we do expenses. When the euro weakens against the U.S. dollar and Swiss franc, our earnings also decrease. We estimate a 1% strengthening of the Swiss franc against the euro would reduce our earnings before tax by approximately $1.6 million to $1.8 million annually.

We also conduct business in many geographies throughout the world, including Asia Pacific, the United Kingdom, Eastern Europe, Latin America, and Canada. Fluctuations in these currency exchange rates against the U.S. dollar can also affect our operating results. The most significant of these currency exposures is the Chinese renminbi. The impact on our earnings before tax of the Chinese renminbi weakening 1% against the U.S. dollar is a reduction of approximately $2.3 million to $2.5 million annually.

In addition to the effects of exchange rate movements on operating profits, our debt levels can fluctuate due to changes in exchange rates, particularly between the U.S. dollar, the Swiss franc, and euro. Based on our outstanding debt at March 31, 2021, we estimate that a 5% weakening of the U.S. dollar against the currencies in which our debt is denominated would result in an increase of approximately $33.3 million in the reported U.S. dollar value of our debt.

### Forward-Looking Statements Disclaimer

*You should not rely on forward-looking statements to predict our actual results. Our actual results or performance may be materially different than reflected in forward-looking statements because of various risks and uncertainties, including statements about expected revenue growth and long-term impacts of the COVID-19 pandemic. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or “continue.”*

*We make forward-looking statements about future events or our future financial performance, including earnings and sales growth, earnings per share, strategic plans and contingency plans, growth opportunities or economic downturns, our ability to respond to changes in market conditions, customer demand, our competitive position, pricing, our supply chain, adequacy of our facilities, access to and the costs of raw materials, shipping and supplier costs, gross margins, planned research and development efforts and product introductions, capital expenditures, cash flow, tax-related matters, the impact of foreign currencies, compliance with laws, effects of acquisitions, and the impact of the COVID-19 pandemic on our businesses.*

*Our forward-looking statements may not be accurate or complete, and we do not intend to update or revise them in light of actual results. New risks also periodically arise. Please consider the risks and factors that could cause our results to differ materially from what is described in our forward-looking statements, including the uncertain duration and severity of the COVID-19 pandemic. See in particular “Factors Affecting Our Future Operating Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2020 and other reports filed with the SEC from time to time.*

## Market risk

As filed, 174 characters.

As of March 31, 2021, there was no material change in the information provided under Item 7A in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

## Controls and procedures

As filed, 702 characters.

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer we have evaluated the effectiveness of our disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures are effective. There were no changes in our internal control over financial reporting during the quarter ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 201 characters.

For the three months ended March 31, 2021 there were no material changes from risk factors disclosed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Filed May 7, 2021.
Source: SEC EDGAR, the filing index for accession 0001037646-21-000019. Last ingested by Listed: Nov 13, 2026, 02:43 ET. No prices; not investment advice.
